To evaluate the efficacy, safety, and tolerability of 10 mg/kg intravenous efgartigimod administered in a fixed-cycle regimen (4 once-weekly infusions with a 4-week intertreatment period) or continuous dosing regimen (every 2 weeks).
No takes yet. Share an insight, caveat, or question.
Bril et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: